Injectable Antiretroviral Drugs: Back to the Future This is another article published yesterday emphasizing injectable antiviral will increase the adherence to the drugs which has been an obstacle in treating PLWH.
“Ibalizumab (IBA) (Trogarzo™), formerly known as TNX355, is a humanized IgG4 monoclonal antibody (MAb), which acts as an entry inhibitor. It binds the CD4 receptor, leading to its conformational change and interfering with its binding with HIV. This first biologic drug was studied for more than a decade with phase I and II trials demonstrating its efficacy and good tolerability profile.
In fact, longacting ART may improve adherence to therapy and extend prophylactic interventions as pre exposure prophylaxis (PrEP) to vulnerable populations. The aim of this manuscript is to give a comprehensive review of injectable antiretrovirals that have been used in the past, which are available now, will be available in the future, and their role in the treatment of HIV infection.
The availability of routes of administration other than oral such as subcutaneous or intravenous may be an advantage and may allow the physicians to closely monitor assumption with direct observed therapy, especially in populations at high risk for interruption (e.g., adolescents) or in PLWH who report drug fatigue.
Pharmacokinetics and pharmacodynamics of injectable drugs allow more regular drug level through adequate therapeutic drug monitoring (TDM), decreasing the likelihood of erratic kinetics due to oral administration (e.g., with or without meals, gastric pH level), and a more stable antiretroviral effect in an optic of treat as prevention (TaSP) and PrEP. Not the least, the access to molecules with a new mechanism of action opens awaited therapeutic chances to those heavilyexperienced patients with few or no available treatment options (e.g.Ibalizumab). "
https://res.mdpi.com/d_attachment/viruses/viruses-13-00228/article_deploy/viruses-13-00228.pdf